Dosing & Uses
Dosage Forms & Strengths
Adjunct to PCI
Prevention of cardiac ischemic complications in patients undergoing PCI
0.25 mg/kg IV bolus over at least 1 min, 10-60 min before start of PCI, THEN
Indicated for prevention of cardiac complications in patients with unstable angina with PCI planned within 24 hr
0.25 mg/kg IV bolus over at least 1 minute, THEN
Stop continuous infusion of abciximab in patients with failed PCIs
Other Indications & Uses
Adjunctive therapy during thrombolysis (off-label)
Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Bleeding, minor (70-82%)
Bleeding, major (17-21%)
Back pain (17.6%)
Chest pain (11.4%)
Injection site pain (3.6%)
Extremity pain (3.5%)
Abdominal pain (3%)
Peripheral edema (1.6%)
Active major bleeding, thrombocytopenia, history of CVA (within 2 years)
Peptic ulcer disease
Recent surgery of trauma, intracranial neoplasm, uncontrolled HTN, vasculitis
Oral anticoagulant use within 7 days increases bleeding risk
Intended for use with aspirin and heparin, and has only been studied in that setting
Increased bleeding risk when used with thrombolytic agents
Monitor for thrombocytopenia
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not known if excreted in breast milk; use caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Chimeric monoclonal antibody; prevents binding of fibrinogen, vWF to glycoprotein IIb/IIIa receptor sites on platelets
Half-life: 30 min
Onset: 10 min (<20% of baseline)
Duration: 72 hr
Metabolism: Through proteolytic cleavage
Platelet binding: Remains bound for 15 days
Peak time: ~30 min (platelet inhibition)
Solution: D5W, NS
Y-site: adenosine, atropine, bivalirudin, diphenhydramine, fentanyl, metoprolol, midazolam
Do not add any other drugs in same IV line
Bolus injection: withdraw through 0.22 micron filter
Infusion: withdraw 4.5 mL (9 mg) through filter into syringe; inject into 250 mL of NS or D5W; final concentration 35 mcg/mL
Do not shake vial
Bolus over at least 1 min
See adult dosing for infusion rate
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs